Thomas Lion

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2081846/publications.pdf

Version: 2024-02-01

		361296	206029
50	2,420	20	48
papers	citations	h-index	g-index
51	51	51	2853
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions. HemaSphere, 2021, 5, e536.	1.2	11
2	Presence of viremia during febrile neutropenic episodes in patients undergoing chemotherapy for malignant neoplasms. American Journal of Hematology, 2021, 96, 719-726.	2.0	1
3	Ponatinib and palbociclib combination in TKI-resistant CML—AÂcase report. Memo - Magazine of European Medical Oncology, 2021, 14, 402-405.	0.3	1
4	Transfer and loss of allergenâ€specific responses via stem cell transplantation: A prospective observational study. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2243-2253.	2.7	3
5	Detection and Monitoring of Lineage-Specific Chimerism by Digital Droplet PCR-Based Testing of Deletion/Insertion Polymorphisms. Biology of Blood and Marrow Transplantation, 2020, 26, 1218-1224.	2.0	8
6	Polylactic acid as a suitable material for 3D printing of protective masks in times of COVID-19 pandemic. PeerJ, 2020, 8, e10259.	0.9	34
7	Adenovirus persistence, reactivation, and clinical management. FEBS Letters, 2019, 593, 3571-3582.	1.3	98
8	Pathogenetic Impact of Bacterial–Fungal Interactions. Microorganisms, 2019, 7, 459.	1.6	31
9	Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica, 2019, 104, 1935-1949.	1.7	93
10	Diagnostic Parameters of Adenoviremia in Pediatric Stem Cell Transplant Recipients. Frontiers in Microbiology, 2019, 10, 414.	1.5	13
11	CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML. EBioMedicine, 2019, 50, 111-121.	2.7	14
12	A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1T315I in Ph+ CML. Leukemia Research, 2019, 78, 36-44.	0.4	3
13	Intestinal Adenovirus Shedding Before Allogeneic Stem Cell Transplantation Is a Risk Factor for Invasive Infection Post-transplant. EBioMedicine, 2018, 28, 114-119.	2.7	38
14	Management of adenovirus infection in patients after haematopoietic stem cell transplantation: Stateâ€ofâ€theâ€art and realâ€life current approach. Reviews in Medical Virology, 2018, 28, e1980.	3.9	75
15	BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib. Haematologica, 2018, 103, e10-e12.	1.7	26
16	Post-transplant Replication of Torque Teno Virus in Granulocytes. Frontiers in Microbiology, 2018, 9, 2956.	1.5	22
17	Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms. Hematological Oncology, 2018, 36, 740-748.	0.8	3
18	Broad-Spectrum Molecular Detection of Fungal Nucleic Acids by PCR-Based Amplification Techniques. Methods in Molecular Biology, 2017, 1508, 257-266.	0.4	4

#	Article	IF	CITATIONS
19	Human cytomegalovirus infection downregulates vitamin-D receptor in mammalian cells. Journal of Steroid Biochemistry and Molecular Biology, 2017, 165, 356-362.	1.2	22
20	Prerequisites for Control of Contamination in Fungal Diagnosis. Methods in Molecular Biology, 2017, 1508, 249-255.	0.4	3
21	Quantitative Analysis of Mutant Subclones in Chronic Myeloid Leukemia: Comparison of Different Methodological Approaches. International Journal of Molecular Sciences, 2016, 17, 642.	1.8	4
22	Risk assessment of relapse by lineage-specific monitoring of chimerism in children undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemia. Haematologica, 2016, 101, 741-746.	1.7	24
23	Modified pan-adenovirus real-time PCR assay based on genome analysis of seventy HAdV types. Journal of Clinical Virology, 2016, 80, 60-61.	1.6	11
24	Peripheral blood late mixed chimerism in leucocyte subpopulations following allogeneic stem cell transplantation for childhood malignancies: does it matter?. British Journal of Haematology, 2016, 173, 905-917.	1.2	17
25	Hypomorphic mutation in TTC7A causes combined immunodeficiency with mild structural intestinal defects. Blood, 2015, 125, 1674-1676.	0.6	20
26	cFinder: definition and quantification of multiple haplotypes in a mixed sample. BMC Research Notes, 2015, 8, 422.	0.6	8
27	Selection of adenovirus-specific and Epstein-Barr virus–specific T cells with major histocompatibility class I streptamers under Good Manufacturing Practice (GMP)–compliant conditions. Cytotherapy, 2015, 17, 989-1007.	0.3	17
28	Identification of RISC-Associated Adenoviral MicroRNAs, a Subset of Their Direct Targets, and Global Changes in the Targetome upon Lytic Adenovirus 5 Infection. Journal of Virology, 2015, 89, 1608-1627.	1.5	25
29	First-in-Man Clinical Results With Good Manufacturing Practice (GMP)-compliant Polypeptide-expanded Adenovirus-specific T Cells After Haploidentical Hematopoietic Stem Cell Transplantation. Journal of Immunotherapy, 2014, 37, 245-249.	1.2	42
30	High-Quality DNA from Fingernails for Genetic Analysis. Journal of Molecular Diagnostics, 2014, 16, 459-466.	1.2	12
31	Development of treatment and clinical results in childhood AML in Austria (1993–2013). Memo - Magazine of European Medical Oncology, 2014, 7, 63-74.	0.3	4
32	Screening for adenoviruses in haematological neoplasia: High prevalence in mantle cell lymphoma. European Journal of Cancer, 2014, 50, 622-627.	1.3	7
33	Adenovirus Infections in Immunocompetent and Immunocompromised Patients. Clinical Microbiology Reviews, 2014, 27, 441-462.	5.7	626
34	Combinatorial targeting of 2 different steps in adenoviral DNA replication by herpes simplex virus thymidine kinase and artificial microRNA expression for the inhibition of virus multiplication in the presence of ganciclovir. BMC Biotechnology, 2013, 13, 54.	1.7	5
35	An adenoviral vector-based expression and delivery system for the inhibition of wild-type adenovirus replication by artificial microRNAs. Antiviral Research, 2013, 97, 10-23.	1.9	30
36	Short-Term In-Vitro Expansion Improves Monitoring and Allows Affordable Generation of Virus-Specific T-Cells against Several Viruses for a Broad Clinical Application. PLoS ONE, 2013, 8, e59592.	1.1	32

#	Article	IF	CITATIONS
37	Prevalence and Clinical Course of Viral Upper Respiratory Tract Infections in Immunocompromised Pediatric Patients With Malignancies or After Hematopoietic Stem Cell Transplantation. Journal of Pediatric Hematology/Oncology, 2012, 34, 442-449.	0.3	17
38	Molecular Diagnosis and Management of Viral Infections in Hematopoietic Stem Cell Transplant Recipients. Molecular Diagnosis and Therapy, 2012, 16, 63-77.	1.6	36
39	Inhibition of adenovirus multiplication by short interfering RNAs directly or indirectly targeting the viral DNA replication machinery. Antiviral Research, 2012, 94, 195-207.	1.9	35
40	Targeted expression of herpes simplex virus thymidine kinase in adenovirusâ€infected cells reduces virus titers upon treatment with ganciclovir ⟨i⟩in vitro⟨ i⟩. Journal of Gene Medicine, 2012, 14, 3-19.	1.4	6
41	Towards molecular diagnostics of invasive fungal infections. Expert Review of Molecular Diagnostics, 2009, 9, 397-401.	1.5	22
42	Investigation of Adenovirus Occurrence in Pediatric Tumor Entities. Journal of Virology, 2007, 81, 7629-7635.	1.5	42
43	The Pan-AC assay: a single-reaction real-time PCR test for quantitative detection of a broad range of Aspergillus and Candida species. Journal of Medical Microbiology, 2007, 56, 1167-1173.	0.7	48
44	Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. British Journal of Haematology, 2006, 134, 64-76.	1.2	368
45	Treatment Response and Outcome in Childhood t(1;19)/TCF3-PBX1 Positive Acute Lymphoblastic Leukemia: A Report from the Austrian BFM Group Blood, 2005, 106, 1458-1458.	0.6	1
46	Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood, 2003, 102, 1114-1120.	0.6	333
47	Monitoring of Residual Disease in Chronic Myelogenous Leukemia by Quantitative Polymerase Chain Reaction and Clinical Decision Making. Blood, 1999, 94, 1486-1488.	0.6	11
48	Monitoring of Residual Disease in Chronic Myelogenous Leukemia by Quantitative Polymerase Chain Reaction and Clinical Decision Making. Blood, 1999, 94, 1486-1488.	0.6	7
49			

4